SAB Biotherapeutics ( ($SABS) ) has provided an update. On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with ...

Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027MIAMI, Dec. 18, 2025 ...

SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...

The Staff Accounting Bulletin (SAB) 121 rule was introduced by the SEC in March 2022 as part of its efforts to regulate cryptocurrency custody. It required financial institutions to list any crypto ...

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed ...

MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

SAB 121 required banks and other traditional financial institutions to hold customers' crypto assets as liabilities on their balance sheets Banks can now hold their customers' Bitcoin and other crypto ...

SIOUX FALLS, S.D., April 13, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces ...

SAB Events & Governance Now Media Ltd. ( ($IN:SABEVENTS) ) has issued an update. SAB Events & Governance Now Media Limited has announced that its ...

SAB has launched a new, more modern logo. Its CEO believes better times lie ahead for South Africa thanks to a growing youthful population. A merged Heineken and Distell group could bring more ...